▁of ▁resistance . ▁ ▁A ▁few ▁ant ib iot ics ▁have ▁received ▁market ing ▁authorization ▁in ▁the ▁last ▁seven ▁years . ▁The ▁ce phal os por in ▁ce ft ar oline ▁and ▁the ▁lip og ly cope pt ides ▁or it av anc in ▁and ▁tel av anc in ▁for ▁the ▁treatment ▁of ▁ac ute ▁b acter ial ▁skin ▁and ▁skin ▁structure ▁in fection ▁and ▁community - ac quired ▁b acter ial ▁p neum onia . ▁The ▁lip og ly cope pt ide ▁dal b av anc in ▁and ▁the ▁ox az olid in one ▁ted iz olid ▁has ▁also ▁been ▁approved ▁for ▁use ▁for ▁the ▁treatment ▁of ▁ac ute ▁b acter ial ▁skin ▁and ▁skin ▁structure ▁in fection . ▁The ▁first ▁in ▁a ▁new ▁class ▁of ▁narrow ▁spectrum ▁macro cyc lic ▁ant ib iot ics , ▁fid ax omic in , ▁has ▁been ▁approved ▁for ▁the ▁treatment ▁of ▁C . ▁diff icile ▁col itis . ▁New ▁ce phal os por in - la ct am ase ▁in hib itor ▁combinations ▁also ▁approved ▁include ▁ce ft az id ime - av ib act am ▁and ▁ce ft ol oz ane - av ib act am ▁for ▁complicated ▁ur inary ▁tract ▁in fection ▁and ▁int ra - ab dom inal ▁in fection . ▁ ▁Stre pt omy ces ▁research ▁is ▁expected ▁to ▁provide ▁new ▁ant ib iot ics , ▁including ▁treatment ▁against ▁MR SA ▁and ▁in fe ctions ▁resist ant ▁to ▁commonly ▁used ▁medic ation . ▁E ff ort s ▁of ▁John ▁In nes